Groupe la Francaise’s Viking Therapeutics VKTX Stock Holding History

Groupe la Francaise’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,700	Closed	-$235K	–	774
2025 Q3	$235K	Buy	+10,700	New	+$319K	﹤0.01%	402

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Groupe la Francaise's VKTX Position: Q4 2025 in Review

Groupe la Francaise sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 10,700 shares — an estimated $235K sold.

Groupe la Francaise first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $235K in Q3 2025. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Groupe la Francaise reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Groupe la Francaise sold 10,700 Viking Therapeutics shares in Q4 2025, an estimated $235K.
Groupe la Francaise first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
Groupe la Francaise's Viking Therapeutics position peaked at $235K in Q3 2025.
424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.